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Background
Obesity is a major public health issue in Brazil and in the
world, increasing the rate of mortality due to comorbid-
ities like: type-2 diabetes mellitus (DM2), arterial hyper-
tension (AH), dyslipidemias, among others. Conventional
obesity treatments show little effect in the long term, lead-
ing to an increase in the search for bariatric surgery as an
alternative for the control and healing of comorbidities.
Objective
To evaluate type-2 diabetes mellitus, arterial hypertension
and dyslipidemia in patients submitted to Roux-En-Y Gastric
Bypass Surgery (RYGB) in the late post-operative period.
Materials and Methods
Retrospective analysis of 59 patients from PROCIBA (bar-
iatric surgery program of a University Hospital at Rio de
Janeiro). Anthropometric (Height and Corporal Weight)
and laboratorial (LDL, HDL, VLDL, Triglycerides (TG)
and Glucose) data at pre-operative and post-operative per-
iods accessed over medical records. Data comparison was
conducted through ANOVA post-hoc Bonferroni test for
anthropometric data and paired T-test for laboratorial
data. A value of p<0.05 was considered as significant.
Results
83% of patients were female, with a mean age of 43±11
yrs.-old and 52% had completed high school education
(Figure 1). Post-operative mean time was 7±3 yrs. Weight
and body mass index (BMI) reduction were registered
post-operatively (133±24 kg vs 91±22 kg and 49±8 kg/m2
vs 33±6 kg/m2, respectively, p<0.05) (Figure 2). Lower
laboratory blood test values were registered post-opera-
tively for glucose (101.00±26.99 vs 89,11±15.19, p=0.014),
total cholesterol (179.00±37.95 vs 167.48±28.50, p <
0.016), LDL (104.30±33.12 vs 91.46±24.58, p=0.016),
VLDL (25.40±11.12 vs 15.68±7.40, p< 0.01), TG (143.35
±86,35 vs 82.45±37.39, p < 0.01), although higher HDL
levels was registered (43.53±8.23 vs 57.90±15.60, p <0.01 )
(table 2). Prevalence in the pre-operative period for AH,
DM2 and dyslipidemia were 76%, 36% and 27%, respec-
tively. At the end of this study, 40% of patients were still in
treatment for SAH (Figure 3). Remission for diabetes and
dyslipidemia was registered in 81% and 94% patients,
respectively (Figure 3).
Conclusion
RYGB has shown an effective procedure in the long
term, leading to weight loss and remission for DM2 and
dyslipidemia.
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Figure 2 Assessment of body weight (A) and BMI (B) prior to surgery, on the day of surgery and after the procedure. ANOVA for repeated
measure with post hoc Bonferroni and significance level 0.05 where: a = p <0.05 vs. weight preoperatively and b = p <0.05 vs. weight the day
of surgery.
Figure 3 Evaluation of glucose and lipemia pre and post-operative.
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